ABBOTT LABORATORIES — Regulatory Filings 2002

Mar 21, 2002

8-K 1 a2073824z8-k.htm 8-K QuickLinks -- Click here to rapidly navigate through this document TOC_END

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

March 15, 2002 Date of Report (Date of earliest event reported)

ABBOTT LABORATORIES (Exact name of registrant as specified in its charter)

User-specified TAGGED TABLE

Illinois (State or other Jurisdiction of Incorporation) 1-2189 (Commission File Number) 36-0698440 (I.R.S. Employer Identification No.)

end of user-specified TAGGED TABLE

100 Abbott Park Road Abbott Park, Illinois 60064-6400 (Address of principal executive offices)(Zip Code)

Registrant's telephone number, including area code: (847) 937-6100

ZEQ.=1,SEQ=1,EFW="2073824",CP="ABBOTT LABORATORIES",DN="1",CHK=990036,FOLIO='blank',FILE='DISK018:[02CHI2.02CHI2072]BA2072A.;6',USER='DINGRAM',CD='20-MAR-2002;21:05' THIS IS THE END OF A COMPOSITION COMPONENT TOC_END

Item 4. Changes in Registrant's Certifying Accountant.

On March 15, 2002, the Board of Directors of Abbott Laboratories ("Abbott") adopted the recommendation of its Audit Committee that Arthur Andersen LLP ("Andersen") be replaced as Abbott's auditors. A new independent public accounting firm has not yet been engaged to act as Abbott's auditors.

Andersen's reports on Abbott's consolidated financial statements for each of the years December 31, 2001 and 2000 did not contain an adverse opinion or disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope or accounting principles.

During the years ended December 31, 2001 and 2000 and through the date hereof, there were no disagreements with Andersen on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure which, if not resolved to Andersen's satisfaction, would have caused Andersen to make reference to the subject matter in connection with its report on Abbott's consolidated financial statements for such years; and there were no reportable events as defined in Item 304(a)(1)(v) of Regulation S-K.

Abbott has provided Andersen with a copy of the foregoing statements. Attached as Exhibit 16 is a copy of Andersen's letter, dated March 21, 2002, stating its agreement with such statements.

Item 7. Financial Statements and Exhibits .

(c) Exhibits.

User-specified TAGGED TABLE

Exhibit No.	Exhibit
16	Letter from Arthur Andersen LLP to the Securities and Exchange Commission dated March 21, 2002

end of user-specified TAGGED TABLE ZEQ.=1,SEQ=2,EFW="2073824",CP="ABBOTT LABORATORIES",DN="1",CHK=961868,FOLIO='blank',FILE='DISK018:[02CHI2.02CHI2072]DE2072A.;7',USER='MWEINST',CD='21-MAR-2002;12:03' THIS IS THE END OF A COMPOSITION COMPONENT TOC_END

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

User-specified TAGGED TABLE

Date: March 21, 2002	ABBOTT LABORATORIES — By:	/s/ THOMAS C. FREYMAN Thomas C. Freyman Senior Vice President, Finance and Chief Financial Officer

end of user-specified TAGGED TABLE ZEQ.=1,SEQ=3,EFW="2073824",CP="ABBOTT LABORATORIES",DN="1",CHK=727431,FOLIO='blank',FILE='DISK018:[02CHI2.02CHI2072]JC2072A.;6',USER='MWEINST',CD='21-MAR-2002;12:04' THIS IS THE END OF A COMPOSITION COMPONENT TOC_END

Exhibit Index

User-specified TAGGED TABLE

Exhibit No.	Exhibit
16	Letter from Arthur Andersen LLP to the Securities and Exchange Commission dated March 21, 2002

end of user-specified TAGGED TABLE ZEQ.=1,SEQ=4,EFW="2073824",CP="ABBOTT LABORATORIES",DN="1",CHK=262212,FOLIO='blank',FILE='DISK018:[02CHI2.02CHI2072]KA2072A.;7',USER='SLYUBOM',CD='21-MAR-2002;12:02' THIS IS THE END OF A COMPOSITION COMPONENT

QuickLinks

TOC_BEGIN

TOC_BEGIN SIGNATURE TOC_BEGIN Exhibit Index SEQ=,FILE='QUICKLINK',USER=MWEINST,SEQ=,EFW="2073824",CP="ABBOTT LABORATORIES",DN="1" TOCEXISTFLAG